Browse UBE2G2

Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00179 Ubiquitin-conjugating enzyme
Function

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes 'Lys-48'-linked polyubiquitination. Involved in endoplasmic reticulum-associated degradation (ERAD).

> Gene Ontology
 
Biological Process GO:0000209 protein polyubiquitination
GO:0006486 protein glycosylation
GO:0006487 protein N-linked glycosylation
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0018196 peptidyl-asparagine modification
GO:0018279 protein N-linked glycosylation via asparagine
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0030970 retrograde protein transport, ER to cytosol
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0032527 protein exit from endoplasmic reticulum
GO:0033157 regulation of intracellular protein transport
GO:0034976 response to endoplasmic reticulum stress
GO:0035456 response to interferon-beta
GO:0035458 cellular response to interferon-beta
GO:0036503 ERAD pathway
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043413 macromolecule glycosylation
GO:0051051 negative regulation of transport
GO:0051224 negative regulation of protein transport
GO:0070085 glycosylation
GO:0070861 regulation of protein exit from endoplasmic reticulum
GO:0070862 negative regulation of protein exit from endoplasmic reticulum
GO:0070936 protein K48-linked ubiquitination
GO:0090317 negative regulation of intracellular protein transport
GO:1903513 endoplasmic reticulum to cytosol transport
GO:1903573 negative regulation of response to endoplasmic reticulum stress
GO:1903828 negative regulation of cellular protein localization
GO:1904152 regulation of retrograde protein transport, ER to cytosol
GO:1904153 negative regulation of retrograde protein transport, ER to cytosol
GO:1904292 regulation of ERAD pathway
GO:1904293 negative regulation of ERAD pathway
GO:1904950 negative regulation of establishment of protein localization
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0061630 ubiquitin protein ligase activity
GO:0061631 ubiquitin conjugating enzyme activity
GO:0061650 ubiquitin-like protein conjugating enzyme activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04120 Ubiquitin mediated proteolysis
hsa04141 Protein processing in endoplasmic reticulum
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-8852135: Protein ubiquitination
R-HSA-8866652: Synthesis of active ubiquitin
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between UBE2G2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of UBE2G2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 2.87; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of UBE2G2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1220.537
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.3570.872
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0570.974
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3680.309
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4340.809
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.290.905
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0150.968
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1160.949
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0780.969
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2820.859
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0330.652
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0160.743
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of UBE2G2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382707.4-7.40.169
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 2213015.4-15.40.131
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UBE2G2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UBE2G2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UBE2G2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UBE2G2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of UBE2G2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between UBE2G2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolUBE2G2
Nameubiquitin-conjugating enzyme E2G 2
Aliases ubiquitin-conjugating enzyme E2G 2 (homologous to yeast UBC7); ubiquitin-conjugating enzyme E2G 2 (UBC7 homo ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting UBE2G2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.